Cotrimoxazole prophylaxis was associated with enteric commensal bacterial resistance among HIV-exposed infants in a randomized controlled trial, Botswana

Kathleen M Powis, Sajini Souda, Shahin Lockman, Gbolahan Ajibola, Kara Bennett, Jean Leidner, Michael D Hughes, Sikhulile Moyo, Erik van Widenfelt, Haruna B Jibril, Joseph Makhema, Max Essex, Roger L Shapiro, Kathleen M Powis, Sajini Souda, Shahin Lockman, Gbolahan Ajibola, Kara Bennett, Jean Leidner, Michael D Hughes, Sikhulile Moyo, Erik van Widenfelt, Haruna B Jibril, Joseph Makhema, Max Essex, Roger L Shapiro

Abstract

Introduction: Despite declining risk of vertical HIV transmission, prophylactic cotrimoxazole (CTX) remains widely used to reduce morbidity and mortality in the event of HIV infection among exposed infants, with an inherent risk of conferring commensal antimicrobial resistance. Using data from a randomized, placebo-controlled trial of infant CTX prophylaxis, we sought to quantify emergence of antibiotic resistance.

Methods: HIV-exposed uninfected infants enrolled in the Botswana Mpepu study were randomized to prophylactic CTX or placebo between 14 and 34 days of life and continued through 15 months. Stool samples were collected from a subset of participating infants at randomization, three, and six months, and stored at -70°C prior to culture. Specimens that grew Escherichia coli (E. coli) or Klebsiella species (Klebsiella spp.) underwent antibiotic susceptibility testing by Kirby Bauer method using CTX (CTX 1.25/23.75 μg) and Amoxicillin (10 μg) in Mueller Hinton agar. Fisher's exact testing was used to compare prevalence of resistance by randomization arm (CTX/placebo).

Results and discussion: A total of 381 stool samples from 220 infants were cultured: 118 at randomization, 151 at three months, and 112 at six-months. E. coli was isolated from 206 specimens and Klebsiella spp. from 138 specimens. Resistance to CTX was common in both E. coli and Klebsiella spp. at the randomization visit (52.2% and 37.7% respectively) and did not differ by study arm. E. Coli isolates from CTX recipients at three and six months had 94.9% and 84.2% CTX resistance, as compared with 51.4% and 57.5% CTX resistance in isolates from placebo recipients (p=0.01). Klebsiella spp. isolates from CTX recipients had 79.0% and 68.8% CTX resistance at three and six months, as compared with 19.1% and 14.3% in isolates from placebo recipients (p<0.01).

Conclusions: HIV-exposed infants randomized to CTX prophylaxis had increased CTX-resistant commensal gastrointestinal bacteria compared with placebo recipients. Additional research is needed to determine the longer-term clinical, microbiologic, and public health consequences of antimicrobial resistance selected by infant CTX prophylaxis.

Trial registration: ClinicalTrials.gov NCT01229761.

Keywords: HIV-exposed infants; commensal organism resistance; cotrimoxazole prophylaxis.

© 2017 The Authors. Journal of the International AIDS Society published by John Wiley & sons Ltd on behalf of the International AIDS Society.

References

    1. World Health Organization . Guidelines on co‐trimoxazole prophylaxis for HIV‐related infections among children, adolescents and adults ‐ recommendations for a public health approach. 2006. [cited 2016 October 21]. Available from: .
    1. World Health Organization, UNICEF . Towards Universal Access: Scaling priority HIV/AIDS interventions in the health sector. 2008. [cited 2016 October 21]. Available from: .
    1. UNAIDS . Report on the Global HIV/AIDS Epidemic. 2008. [cited 2016 October 23]. Available from: .
    1. Baggaley R, Hensen B, Ajose O, Grabbe KL, Wong VJ, Schilsky A, et al. From caution to urgency: the evolution of HIV testing and counselling in Africa. Bull World Health Organ. 2012;90(9):652–658B.
    1. l . Children and AIDS ‐ Third Stocktaking Report, 2008. 2008. [cited 2016 October 23]. Available from: .
    1. Mulenga V, Ford D, Walker AS, Mwenya D, Mwansa J, Sinyinza F, et al. Effect of cotrimoxazole on causes of death, hospital admissions and antibiotic use in HIV‐infected children. AIDS. 2007;21(1):77–84.
    1. Chintu C, Bhat GJ, Walker AS, Mulenga V, Sinyinza F, Lishimpi K, et al. Co‐trimoxazole as prophylaxis against opportunistic infections in HIV‐infected Zambian children (CHAP): a double‐blind randomised placebo‐controlled trial. Lancet. 2004;364(9448):1865–71.
    1. Crook AM, Turkova A, Musiime V, Bwakura‐Dangarembizi M, Bakeera‐Kitaka S, Nahirya‐Ntege P, et al., Tuberculosis incidence is high in HIV‐infected African children but is reduced by co‐trimoxazole and time on antiretroviral therapy. BMC Med. 2016;14:50.
    1. UNAIDS . Prevention Gap Report. 2016. Available from: .
    1. Munier AL, de Lastours V, Varon E, Donay JL, Porcher R, Molina JM. , et al. Invasive pneumococcal disease in HIV‐infected adults in France from 2000 to 2011: antimicrobial susceptibility and implication of serotypes for vaccination. Infection. 2013;41(3):663–8.
    1. Anglaret X, Chêne G, Attia A, Toure S, Lafont S, Combe P, et al. Early chemoprophylaxis with trimethoprim‐sulphamethoxazole for HIV‐1‐infected adults in Abidjan, Cote d'Ivoire: a randomised trial. Cotrimo‐CI Study Group. Lancet. 1999;353(9163):1463–8.
    1. Nunn AJ, Mwaba P, Chintu C, Mwinga A, Darbyshire JH, Zumla A, et al. Role of co‐trimoxazole prophylaxis in reducing mortality in HIV infected adults being treated for tuberculosis: randomised clinical trial. BMJ. 2008;337: a257.
    1. Davis NL, Barnett EJ, Miller WC, Dow A, Chasela CS, et al. Impact of daily cotrimoxazole on clinical malaria and asymptomatic parasitemias in HIV‐exposed, uninfected infants. Clin Infect Dis. 2015;61(3):368–74.
    1. Mbeye NM, ter Kuile FO, Davies MA, Phiri KS, Egger M, et al. Cotrimoxazole prophylactic treatment prevents malaria in children in sub‐Saharan Africa: systematic review and meta‐analysis. Trop Med Int Health. 2014:19(9):1057–67.
    1. Shapiro RL, Hughes M, Powis K, Ajibola G, Bennett K, Moyo S, et al. Similar mortality with cotrimoxazole vs placebo in HIV‐exposed uninfected children In: 2016 Conference on Retroviruses and Opportunistic Infections. Boston, MA; 2016.
    1. Clinical and Laboratory Standards Institute . Performance standards for antimicrobial susceptibility testing; twenty‐fifth informational supplement. Wayne, PA: Clinical and Laboratory Standards Institute; 2015. CLSI document M100‐S25 (ISBN 1‐56238‐989‐0 [Print]; ISBN 1‐56238‐990‐4 [Electronic]).
    1. Shapiro RL, Kumar L, Phillips‐Howard P, Wells JG, Adcock P, et al. Antimicrobial‐resistant bacterial diarrhea in rural western Kenya. J Infect Dis. 2001;183(11):1701–4.
    1. Hamel MJ, Greene C, Chiller T, Ouma P, Polyak C, et al. Does cotrimoxazole prophylaxis for the prevention of HIV‐associated opportunistic infections select for resistant pathogens in Kenyan adults? Am J Trop Med Hyg. 2008;79(3):320–30.
    1. Cotton MF, Wasserman E, Smit J, Whitelaw A, Zar HJ. High incidence of antimicrobial resistant organisms including extended spectrum beta‐lactamase producing Enterobacteriaceae and methicillin‐resistant Staphylococcus aureus in nasopharyngeal and blood isolates of HIV‐infected children from Cape Town, South Africa. BMC Infect Dis. 2008;8:40.
    1. Mermin J, Lule J, Ekwaru JP, Malamba S, Downing R, Ransom R, et al. Effect of co‐trimoxazole prophylaxis on morbidity, mortality, CD4‐cell count, and viral load in HIV infection in rural Uganda. Lancet. 2004;364(9443):1428–34.
    1. Mwansa J, Mutela K, Zulu I, Amadi B, Kelly P. Antimicrobial sensitivity in enterobacteria from AIDS patients, Zambia. Emerg Infect Dis. 2002;8(1):92–3.
    1. Uma B, Prabhakar K, Rajendran S, Kavitha K, Sarayu YL. Antibiotic sensitivity and plasmid profiles of Escherichia coli isolated from pediatric diarrhea. J Glob Infect Dis. 2009;1(2):107–10.
    1. Akingbade O, Balogun S, Ojo D, Akinduti P, Okerentugba PO, Nwanze JC, et al. Resistant plasmid profile analysis of multidrug resistant Escherichia coli isolated from urinary tract infections in Abeokuta, Nigeria. Afr Health Sci. 2014;14(4):821–8.
    1. Osterblad M, Hakanen A, Manninen R, Leistevuo T, Peltonen R, et al. A between‐species comparison of antimicrobial resistance in enterobacteria in fecal flora. Antimicrob Agents Chemother. 2000;44(6):1479–84.
    1. Walker WA. Initial intestinal colonization in the human infant and immune homeostasis. Ann Nutr Metab. 2013;63 Suppl 2:8–15.
    1. Gensollen T, Iyer SS, Kasper DL, Blumberg RS. How colonization by microbiota in early life shapes the immune system. Science. 2016;352(6285):539–44.
    1. Sommer F, Backhed F. The gut microbiota–masters of host development and physiology. Nat Rev Microbiol. 2013;11(4):227–38.
    1. Brahmbhatt H, Kigozi G, Wabwire‐Mangen F, Serwadda D, Lutalo T, Nalugoda F, et al. Mortality in HIV‐infected and uninfected children of HIV‐infected and uninfected mothers in rural Uganda. J Acquir Immune Defic Syndr. 2006;41(4):504–8.
    1. Chilongozi D, Wang L, Brown L, Taha T, Valentine M, Emel L, et al. Morbidity and mortality among a cohort of human immunodeficiency virus type 1‐infected and uninfected pregnant women and their infants from Malawi, Zambia, and Tanzania. Pediatr Infect Dis J. 2008;27(9):808–14.
    1. Marinda E, Humphrey JH, Iliff PJ, Mutasa K, Nathoo KJ, et al. Child mortality according to maternal and infant HIV status in Zimbabwe. Pediatr Infect Dis J. 2007;26(6):519–26.
    1. Newell ML, Coovadia H, Cortina‐Borja M, Rollins N, Gaillard P, Dabis F, et al. Mortality of infected and uninfected infants born to HIV‐infected mothers in Africa: a pooled analysis. Lancet. 2004;364(9441):1236–43.
    1. Shapiro RL, Lockman S, Kim S, Smeaton L, Rahkola JT, et al. Infant morbidity, mortality, and breast milk immunologic profiles among breast‐feeding HIV‐infected and HIV‐uninfected women in Botswana. J Infect Dis. 2007;196(4):562–9.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel